Company intelligence / Profile preview

Tessellate BIO

Amsterdam, North Holland, Netherlandsuk.linkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Tessellate BIO aims to become a global leader in precision oncology by redefining synthetic lethality for large unserved cancer patient populations. Its lead preclinical program targets cancers reliant on Alternative Lengthening of Telomeres through inhibition of the FANCM protein complex. The approach addresses significant unmet needs in oncology, particularly among sarcomas and certain solid tumors where ALT dependency exceeds 60% in some subtypes. The company was founded based on discoveries from academic co-founders Prof. Hilda Pickett and Prof. Claus Azzalin.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Partnerships

Forbion

Beyond the preview

Go deeper on Tessellate BIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tessellate BIO.

Explore the full profile